Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations
Year: 2019
Type: article
Source: The Lancet Haematology
Authors: Jacob D Soumerai, Ai Ni, Mohamed Darif, Anil Londhe, Guan Xing, Yong Mun, Neil E Kay, Tait D Shanafelt, Kari G Rabe, John C Byrd, Asher A Chanan-Khan, Richard R Furman, Peter Hillmen, Jeffrey Jones, John F Seymour, Jeffrey P Sharman, Lucille Ferrante, Mehrdad Mobasher, Thomas Stark, Vijay Reddy, Lyndah K Dreiling, Pankaj Bhargava, Angela Howes, Danelle F James, Andrew D Zelenetz
Institutions: Memorial Sloan Kettering Cancer Center, Harvard University, Massachusetts General Hospital, Genentech, Mayo Clinic, Stanford Medicine, Stanford University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Mayo Clinic in Florida, St James's University Hospital, The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, Willamette Valley Cancer Institute and Research Center, Pharmacyclics (United States)
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W2944976872